Balchem Corp 8-K, filed Dec 6, 2022
Balchem Corp (BCPC)
8-K
2022-12-06
For: 2022-12-05
View Original
Added on
April 11, 2026
About this 8-K
Balchem Corp filed this 8-K on December 6, 2022, reporting on events of December 5, 2022.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 5, 2022
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (845 )
326-5600
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which
registered
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
On December 6, 2022, Balchem Corporation (the “Company”) issued a press release announcing a dividend declared by the Company's Board of Directors on
December 5, 2022. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01 |
Financial Statements and Exhibits.
|
(d) Exhibits
|
Exhibit Number
|
Description
|
|
Press Release dated December 6, 2022
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
BALCHEM CORPORATION
|
|||
|
(Registrant)
|
|||
|
By:
|
/s/ Hatsuki Miyata
|
||
|
Hatsuki Miyata
|
|||
|
Executive Vice President, General Counsel and Secretary
|
|||
|
Date: December 6, 2022
|
|||
Exhibit 99.1
 |
 |
FOR IMMEDIATE RELEASE
Balchem Corporation Announces Dividend
Montvale, New Jersey, December 6, 2022. Balchem Corporation (NASDAQ: BCPC) today announced that on December 5, 2022, its Board of Directors declared a dividend on its shares of common stock equal to $0.71 per share on the Company’s issued and outstanding Common Stock, to be
payable on January 20, 2023 to stockholders of record at the close of business on December 27, 2022. This dividend represents an 10.9% increase over last year’s annual dividend.
Ted Harris, Balchem’s Chairman, President, and CEO, said, “Balchem has a long-standing commitment to an annual dividend and we are pleased to announce the
continuation of that commitment. This dividend represents the fourteenth consecutive increase in our annual dividend, reflecting both the consistently outstanding financial performance the company has delivered and the Board’s continued confidence
in our long-term strategies.”
About Balchem Corporation
Balchem Corporation develops, manufactures and markets specialty ingredients that improve and enhance the health and well-being of life on the planet,
providing state-of-the-art solutions and the finest quality products for a range of industries worldwide. The company reports three business segments: Human Nutrition & Health; Animal Nutrition & Health; and Specialty Products. The Human
Nutrition & Health segment delivers customized food and beverage ingredient systems, as well as key nutrients into a variety of applications across the food, supplement and pharmaceutical industries. The Animal Nutrition & Health segment
manufactures and supplies products to numerous animal health markets. Through Specialty Products, Balchem provides specialty-packaged chemicals for use in healthcare and other industries, and also provides chelated minerals to the micronutrient
agricultural market.
Forward-Looking Statements
This release contains forward-looking statements, which reflect Balchem’s expectation or belief concerning future events that involve
risks and uncertainties. Balchem can give no assurance that the expectations reflected in forward-looking statements will prove correct and various factors could cause results to differ materially from Balchem’s expectations, including risks and
factors identified in Balchem’s annual report on Form 10-K for the year ended December 31, 2021 and Form 10-Q for the quarterly period ended June 30, 2022.
Forward-looking statements are qualified in their entirety by the above cautionary statement. Balchem assumes no duty to update its outlook
or other forward-looking statements as of any future date.
|
Contact:
|
Jacqueline Yarmolowicz
|
|
Balchem Corporation (Telephone: 845-326-5600)
|
2